Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (37)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boven, E.
Right arrow Articles by Pinedo, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boven, E.
Right arrow Articles by Pinedo, H. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:321-324, 1993
© 1993 European Society for Medical Oncology

research-article

Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer

E. Boven1,, E. Venema-Gaberscek1, C. A. M. Erkelens1, M. C. Bissery2 and H. M. Pinedo1

1Department of Medical Oncology, Free University Hospital Amsterdam, The Netherlands
2Rhone-Poulenc Rorer, Centre de Recherche de Vitry Alfortville Vitry sur Seine, France

Correspondence to: Mrs. E. Boven, MD, PhD Department of Medical Oncology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

BACKGROUND:: The new cytostatic agent taxol has clearly demonstrated its effectiveness in ovarian cancer patients. The synthesis of drugs related to taxol could overcome its limited natural supply and may have additional benefits, such as greater efficacy or better solubility. Taxotere (RP 56976, NSC 628503) is such a compound. We investigated the drug for its antitumor activity in human ovarian cancer xenografts

MATERIALS AND METHODS:: Five human ovarian cancer lines were selected with respect to differences in histological subtypes, growth rates and chemosensitivity to conventional cytostatic agents. Tumors were implanted as fragments s.c. into both flanks of female nude mice (Hsd: athymic nude-nu). Treatment was started in groups of 5-8 mice at the time mean tumor volume measured 50-150 mm3. Taxotere was injected i.v. weekly x 2. Drug efficacy was expressed as the maximum percentage of growth inhibition of treated tumors as compared to control tumors.

RESULTS:: At the maximum tolerated dose of 15-20 mg/kg for weekly i.v. x 2 injections, taxotere induced a mean weight loss of 10%–15% of the initial weight within 2 weeks after the first injection. The maximum percentage of growth inhibition obtained was ≥ 50% in 4/5 lines and ≥90% in 3/5 lines. In 2 lines, taxotere appeared more effective than cisplatin, cyclophosphamide or doxorubicin, drugs studied previously at maximum tolerated doses in the same tumor lines.

CONCLUSION:: Our findings in human ovarian cancer xenografts hold promise for the efficacy of taxotere in this type of disease in the clinic.

antitumor activity, human tumor xenografts, ovarian cancer, taxotere


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
B. Gu, L. Espana, O. Mendez, A. Torregrosa, and A. Sierra
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus
Carcinogenesis, December 1, 2004; 25(12): 2293 - 2301.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei, C. E. Klein, H. Kastrissios, R. M. Goldberg, S. R. Alberts, H. C. Pitot, J. A. Sloan, J. M. Reid, L. J. Hanson, P. Atherton, et al.
Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity
J. Clin. Oncol., March 1, 2000; 18(5): 1116 - 1116.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.